期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 11, 期 7, 页码 657-667出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.2013.811924
关键词
Acinetobacter baumannii; -lactamases; -lactams; carbapenemases; carbapenems; Enterobacteriaceae; Latin America; Pseudomonas aeruginosa; resistance
资金
- Merck Sharp Dohme
- Merck Colombia
- Janssen-Cilag SA
- Novartis
- Pfizer SA
- AstraZeneca Colombia SA
- Johnson Johnson
- Pfizer
- Merck
- BD
- AstraZeneca
- Novartis Inc
- Pfizer Inc.
- MSD Inc.
- sanofi-aventis Inc.
- United Medicals Brazil
- Merck Sharp Dhome
Enterobacteriaceae and non fermenting Gram-negative bacilli have become a threat to public health, in part due to their resistance to multiple antibiotic classes, which ultimately have led to an increase in morbidity and mortality. -lactams are currently the mainstay for combating infections caused by these microorganisms, and -lactamases are the major mechanism of resistance to this class of antibiotics. Within the -lactamases, carbapenemases pose one of the gravest threats, as they compromise one of our most potent lines of defense, the carbapenems. Carbapenemases are being continuously identified worldwide; and in Latin America, numerous members of these enzymes have been reported. In this region, the high incidence of reports implies that carbapenemases have become a menace and that they are an issue that must be carefully studied and analyzed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据